Nature·5 min read·hard
Multitargeted comparative evaluation suggests 2-Aoeobenoxmide shows favourable in silico binding compared to Tucatinib against ERα, HER2, AKT1, EGFR, and PIK3CA in breast cancer
✦AI Summary
Researchers have identified a natural compound, 2-Aoeobenoxmide, that shows potential for treating drug-resistant breast cancer by targeting multiple oncogenic proteins. In silico evaluations suggest it may have superior binding affinity compared to the FDA-approved drug Tucatinib.
Why it matters
This study offers a potential new therapeutic pathway for patients with resistant breast cancer, which remains a major global health challenge.
Scientific Reports ( 2026 ) Cite this article
sciencehealth
Political Bias
Center
LeftLean LCenterLean RRight
Confidence: 95%
The article reports on scientific research findings without political or social commentary.
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in